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Biochemical markers of renal osteodystrophy in pediatric patients
undergoing CAPD/CCPD. Serum intact PTH [1—84] levels were evalu-
ated as a potential non-invasive method for the diagnosis of renal
osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone
biopsy samples were obtained from 55 patients, aged 13 5 (X SD)
years, undergoing CAPD/CCPD for 29 13 months; osteitis fibrosa was
present in 34 cases, mild lesions of secondary hyperparathyroidism in
six, 15 had adynamic lesions, and 13 were classified as normal histol-
ogy. Serum calcium levels were higher in patients with adynamic bone
or normal bone histology than in those with secondary hyperparathy-
roidism, whereas serum phosphorus, alkaline phosphatase and PTH
levels were greater in patients with osteitis fibrosa. The combination of
a serum PTH level >200 pg/ml and a serum calcium value <10 mgldl
was 85% sensitive and 100% specific for identifying patients with
high-turnover lesions of bone. Serum PTH values <200 pg/ml were
100% sensitive but only 79% specific for patients with adynamic bone;
specificity increased to 92%, however, using the combined criteria of a
PTH level <150 pglml and a serum calcium level >10 mgldl. Higher
serum calcium levels and serum PTH values within or below the normal
range characterize patients with the adynamic lesion of renal osteodys-
trophy. Serum PTH levels of approximately 200 pg/mI are useful for
distinguishing patients with low-turnover lesions of renal osteodystro-
phy from those with secondary hyperparathyroidism.
Secondary hyperparathyroidism develops in most patients
with chronic renal failure. Accordingly, osteitis fibrosa has been
the most common histologic lesion of bone both in adults and in
children undergoing hemodialysis or peritoneal dialysis [1—4].
Recent reports suggest, however, that the prevalence of low-
turnover skeletal disorders, in particular the adynamic or aplas-
tic lesion of renal osteodystrophy, has increased substantially.
Thus, as many as 66% of adult patients receiving peritoneal
dialysis have evidence of adynamic bone on histologic evalua-
tion [5], and a substantial proportion of these do not have
diabetes or evidence of bone aluminum deposition, factors
previously recognized as causes of the adynamic lesion in
patients with chronic renal failure [6, 7].
Although the long-term consequences of adynamic bone have
yet to be fully characterized, hypercalcemia commonly occurs
in this disorder, particularly during treatment with calcium
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carbonate [5, 81. This cause of hypercalcemia in patients
undergoing regular dialysis must be distinguished from that due
to severe secondary hyperparathyroidism; parathyroidectomy
may be required to correct hypercalcemia in patients with
advanced osteitis fibrosa [3], whereas parathyroid surgery is not
indicated in patients with the adynamic lesion of renal osteodys-
trophy since serum PTH levels are relatively low in this
condition. Bone biopsy is currently the only reliable method for
distinguishing pediatric patients with advanced secondary hy-
perparathyroidism from those with adynamic lesions of bone [2,
5].
Several reports have documented the value of PTH measure-
ments using the immunoradiometric (IRMA) assay for intact
hormone in adults undergoing dialysis [5, 9, 10]. Only one study
has been done, however, using this assay in children receiving
hemodialysis [11], and no data are available for children under-
going peritoneal dialysis. In the current study, the serum levels
of intact PTH, calcium and alkaline phosphatase were evalu-
ated as potential non-invasive predictors of renal osteodystro-
phy in children undergoing CAPD/CCPD.
Methods
Histomorphometric and biochemical data from all pediatric
patients treated by CAPD or CCPD who had undergone bone
biopsy at this institution to assess renal osteodystrophy be-
tween 1983 and 1992 were reviewed. From a total of 156 biopsy
specimens, concurrent determinations of serum parathyroid
hormone (PTH) levels using the immunoradiometric assay
(IRMA) for intact hormone were available in 71 specimens.
This subset of patients was selected for further analysis after
one patient with aluminum-related bone disease and two pa-
tients with mixed lesions of renal osteodystrophy were ex-
cluded because of the small number of cases with these two
disorders. None of the patients with osteomalacia had a con-
current PTH determination by IRMA assay.
Sixty-eight biopsies were available from 55 patients, 29 boys
and 26 girls; the mean age of patients at the time of bone biopsy
was 13 5 years, and they had been treated with CAPD or
CCPD for 29 13 months. All patients used dialysate solutions
(Dianeal, Baxter, Deerfield, Illinois, USA) containing 3.5 mEq/
liter of calcium, and glucose concentrations were adjusted
according to the needs for ultrafiltration. All but eight patients
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were receiving calcium carbonate exclusively as a phosphate-
binding agent at the time of biopsy; eight patients had been
given a combination of aluminum hydroxide and calcium car-
bonate. Although most patients had been treated with daily
doses of oral calcitriol for the management of renal osteodys-
trophy, four patients had received intermittent doses of oral
calcitriol three times per week, and three others had been given
thrice weekly doses of calcitriol intraperitoneally. In all cases,
the dose of calcitriol was adjusted to maintain serum calcium
levels between 10.5 to 11.0 mg/dl [12]. All studies were ap-
proved by the UCLA Human Subject Protection Committee,
and informed consent was obtained from all patients and/or
their parents.
Bone biopsies were obtained from the anterior iliac crest
using a modified Bordier trephine after double tetracycline
labeling as previously described [2]. Serum samples for mea-
surements of calcium, phosphorus, alkaline phosphatase, and
PTH levels were obtained at the time of bone biopsy.
Bone histomorphometry
Quantitative histomorphometry of bone was done as previ-
ously described [2], and the terminology established by the
Nomenclature Committee of the American Society for Bone
and Mineral Research was used for all results [13]. All histo-
morphometric data refer to measurements in two dimensions
[13]. Reference values for normal subjects were obtained from
iliac crest bone biopsies done in 27 normal children between the
ages of 2.5 and 17 years who had undergone elective orthopedic
or urologic surgical procedures. None of these subjects had
clinical or biochemical evidence of metabolic bone disease,
diabetes, or renal insufficiency. All were physically active
according to age [2], and none had a history of treatment with
corticosteroids, anticonvulsant medications, or vitamin D prep-
arations.
Patients with renal osteodystrophy were classified according
to the following histomorphometric criteria based upon the
reference values established in normal children: osteitis fibro-
sa—osteoid area <12%, evidence of tissue fibrosis and bone
formation rate (BFR, tissue referent) >613 tm2/mm2/day; mild
lesion of secondary hyperparathyroidism—osteoid area <12%,
no tissue fibrosis and BFR >613 prn2/mm2/day; normal bone
histology—no fibrosis, osteoid volume >1.0% but <12% and
BFR >97 but <613 m2/mm2/day; adynamic bone—osteoid
area <12%, no fibrosis and BFR <97 prn2/mm2/day; osteoma-
lacia—osteoid area >12%, no fibrosis and BFR <97 jsm2/mm2/
day; mixed lesion—osteoid area >15% and fibrosis present [2].
Serum calcium, phosphorus and alkaline phosphatase levels
were determined using a Technicon Autoanalyzer II. Serum
PTH was measured by the immunoradiometric assay described
by Nussbaum et al [14]; values for subjects with normal renal
function range from 10 to 65 pg/ml using this assay.
Statistical analysis
All results are presented as the mean one standard devia-
tion, Statistical analysis of the data was done using one-way
analysis of variance with contrasts and chi-square analysis [6].
Sensitivity, specificity and positive predictive value (PPV) were
determined for selected levels of PTH in serum for several
types of renal bone disease. Sensitivity is defined as the ability
of a biochemical parameter to identify patients with selected
Table 1. Patient characteristics and serum biochemical
determinations according to histologic subtype of renal
osteodystrophy
Osteitis
fibrosa
(N = 34)
Mild(N = 6)
Normal
histology(N = 13)
Adynamic/
aplastic(N = 15)
Age 15±4 10±7 13±5 12±4
years
Duration ofCCPD 30 26 14 12 44 36 20 17
months
Calcium 8.9 0.9 9.0 1.4 9.9 1,0b 10.2 0,7b
mg/dl
Albumin 3.7 0.5 3.9 0.3 3.9 0.4 3.8 0.4
g/dl
Phosphorus 6.6 1.0w 5.2 1.4 5.7 1.4 5.7 1.9
mg/dl
Alkaline 370 231" 218 181 169 67 102 40
phosphatase
lU/Liter
PTH [1-84] 678 402C 276 ll4 180 141 58 52
pg/mi
a P < 0.01 vs. normal histology
bp < 0.01 vs. osteitis fibrosa and mild
P < 0.001 vs. mild, adynamic and normal histology
"P < 0.01 vs. adynamic and normal histology
P < 0.05 vs. adynamic
histologic lesions of bone within a population; specificity rep-
resents the ability of a biochemical test to exclude those without
a given skeletal lesion. Positive predictive value (PPV) defines
the probability that patients with defined biochemical criteria
actually have a given disorder [15].
Results
Of the 68 bone biopsies obtained with concurrent measure-
ments of serum intact PTH, there was histologic evidence of
osteitis fibrosa in 34 cases, and mild lesions of secondary
hyperparathyroidism were found in six cases; adynamic lesions
of renal osteodystrophy were present in 15 biopsies, and
thirteen were classified as normal histology (Table 1). Patients
with osteitis fibrosa were older than those with other histologic
lesions of renal osteodystrophy, whereas patients with normal
bone histology had been treated with CCPD for the longest
period (Table 1). Only two patients had undergone parathyroid-
ectomy in the past. A total of 17 patients had undergone prior
renal transplantation; of these, nine had osteitis fibrosa, four
had adynamic lesions, and four had normal bone histology.
There were no differences among groups in the number of
patients who had undergone previous parathyroidectomy or
renal transplantation (P = 0.582, Fisher's exact test).
Patients with adynamic bone and those with normal bone
histology had higher serum calcium levels than patients with
secondary hyperparathyroidism, whereas serum albumin levels
did not differ among groups (Table 1). Serum phosphorus and
alkaline phosphatase levels were greater in patients with osteitis
fibrosa than in any of the other histologic subgroups (Table 1).
On average, serum PTH levels were approximately ten times
the upper limit of normal inpatients with overt osteitis fibrosa,
whereas values were less markedly elevated in those with mild
lesions of secondary hyperparathyroidism (Table 1). Serum
PTH levels did not differ substantially between patients with
mild lesions and those with normal bone histology. For the 15
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OF M NH AP
Total
1983—1992 71 26 29 21 6 3
(N 156) (46%) (17%) (19%) (13%) (4%) (2%)
1983—1986 25 15 10 7 6 0
(N = 63) (40%) (24%) (16%) (11%) (9%) (0%)
1987—1992 46 11 19 14 0 3
(N = 93) (50%) (12%) (20%) (15%) (0%) (3%)
Current
study 34 6 13 15 0 0(N 68) (50%) (9%) (19%) (22%) (0%) (0%)
patients with adynamic skeletal lesions, serum PTH levels were
within the normal range in ten patients, whereas values fell
below the lower limit of normal in one (Table 1, Fig. 1).
Overall, the distribution of histologic subtypes of renal os-
teodystrophy in the current study was similar to that seen when
all biopsy specimens obtained during the past 10 years in
pediatric patients receiving CAPD/CCPD were considered (Ta-
ble 2). The prevalence of histologic lesions for patients under-
going biopsy during the first and second five year intervals, that
is, before or after January of 1987, also did not differ substan-
tially (Table 2). Prior to 1987, 11% of biopsy samples demon-
strated adynamic lesions of renal osteodystrophy, whereas 15%
of biopsy samples had adynamic lesions after this date. The
combined prevalence of adynamic bone and normal bone
histology was 27% before January of 1987 and 35% thereafter.
Only one patient evaluated after January of 1987 had aluminum
deposition in bone documented by histochemical staining meth-
ods, and none had aluminum-related bone disease as judged by
criteria previously reported from this laboratory [2].
Several biochemical determinations, including the serum
levels of calcium, phosphorus and PTH, were evaluated as
non-invasive predictors of the type of renal bone disease. Using
the results for PTH alone, values greater than 200 pg/mI were
95% sensitive and 86% specific and for identifying patients with
high-turnover lesions of bone due to secondary hyperparathy-
roidism (Table 3); the PPV for a serum PTH level above 200
pg/mi was 90%. When combined with a serum calcium level less
Positive
predictive
Criteria
Sensitivity Specificity value
%
PTH > 200 pg/mI 95 86 91(N = 38)
VFH > 250 pg/mi 90 89 92(N = 36)
PTH> 300 pg/mi 85 93 94(N = 34)
PTH> 200 pg/mI and 85 100 100
S0 < 10 mg/dI(N = 34)
PTH >200 pg/mI and 65 100 100
Sca < 9.5 mg/dl(N = 26)
PTH >200 pg/mI and 43 100 100
Sca < 9.0 mg/dl(N = 17)
of patients conforming to the specified
than 10 mg/dl, the sensitivity of serum PTH levels above 200
pg/mi decreased to 85% as a marker of high-turnover skeletal
lesions, but the two criteria together excluded all patients with
normal or reduced rates of bone formation (Table 3); thus, PPV
was 100% for this combination of test results. In contrast,
serum alkaline phosphatase levels above 250 lU/liter were 96%
specific but only 55% sensitive in predicting lesions of second-
ary hyperparathyroidism (Table 4).
For patients with the adynamic lesion of renal osteodystro-
phy, serum PTH values less than 200 pg/mI were 100% sensitive
but only 79% specific as an isolated diagnostic criterion; the
PPV for a serum PTH level less than 200 pg/mi was 58% (Table
5). Specificity was enhanced to 89%, however, when the
screening criteria included both a serum PTH level less than 200
pg/mi and a serum calcium level above 10 mgldl (Table 5).
Specificity for the adynamic lesion of renal osteodystrophy was
further increased using the combined criteria of a PTH level less
than 150 pg/mI and a serum calcium level greater than 10 mg/dl,
and the PPV increased to 82%. This approach correctly identi-
fied 11 of 15 patients with adynamic lesions and it excluded all
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Table 2. Prevalence of histologic types of renal osteodystrophy in
the current study and in patients biopsied before and after
January 1987
Fig. 1. Serum PTH 1-84 levels according to
histologic sub-type of renal osteodytrophy in
pediatric patients treated with CAPD/CCPD.
Abbreviations are: OF, osteitis; M, mild
lesion; NH, normal bone histology; AP,
aplastic lesion. Solid lines represent the upper
and lower limit of the assay for PTH.
Osteitis Normal Adynamic/ Mixed
fibrosa Mild histology aplastic Osteomalacia lesion
Table 3. Predictive value of serum PTH and calcium levels for the
diagnosis of high-turnover lesions
N refers to the number
criteria; Sca is serum calcium.
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Table 4. Predictive value of serum alkaline phosphatase
determinations for high- and low-turnover lesions of bone
Positive
predictive
Criteria
Sensitivity Specificity value
%
High-turnover
AP> 250 lU/liter 55 96 96(N 22)
AP> 200 lU/liter 65 82 82
(N = 26)
AP> 150 lU/liter 77 61 61
(N=31)
Low-turnover
AP < 200 lU/liter 100 58 58(N = 15)
AP < 150 lU/liter 80 75 75
(N= 12)
AP < 100 lU/liter 60 90 90
(N = 9)
N refers to the number of patients conforming to the specified
criteria.
Table 5. Predictive value of serum PTH and calcium levels for the
diagnosis of low-turnover lesions
Positive
predictive
Criteria
Sensitivity Specificity value
%
PTH < 200 pg/mI 100 79 58
(N= 15)
PTH < 150 pg/mI 93 89 70(N = 14)
PTH < 100 pg/mI 80 92 75(N = 12)
PTH < 200 pg/mI and 60 89 60
Sca> 10 mg/dl(N = 9)
PTH < 150 pg/nil and 80 92 82
Sea> 10 mg/dl
(N =9)
N refers to the number of patients conforming
criteria; S is serum calcium.
to the specified
patients with either normal bone histology or secondary hyper-
parathyroidism (Table 5), By comparison, serum alkaline phos-
phatase levels less than 200 lU/liter were 100% sensitive but
only 58% specific for the diagnosis of adynamic lesions (Table
4).
Discussion
In the past, serum biochemical determinations have been
poor predictors of bone histology in pediatric patients undergo-
ing maintenance dialysis [2, 16—19]. Although markedly ele-
vated serum PTH levels generally suggest the presence of
advanced secondary hyperparathyroidism, the use of different
PTH assays with varying degrees of specificity for the intact
hormone and carboxy-terminal PTH fragments can render the
interpretation of results difficult; many studies have found
considerable overlap among serum PTH values using mid-
region or carboxy-terminal assays in patients with various
histologic subtypes of renal osteodystrophy [10, 12]. In con-
trast, PTH determinations using amino-terminal assays have
generally correlated well with bone histomorphometric mea-
surements [20], and they have also been shown to correspond to
varying degrees of renal functional impairment [21].
Two-site immunoradiometric (IRMA) assays that measure
intact parathyroid hormone are now widely available. These
assays have high precision, are relatively free of serum effects,
and provide reliable measurements of intact hormone in the
serum of patients with chronic renal failure [5, 9, 10]. Mathias et
al recently demonstrated the utility of an IRMA PTH assay for
distinguishing between low-turnover and high-turnover lesions
of renal osteodystrophy in adolescents and young adults under-
going regular hemodialysis [4]. Several other reports indicate
that serum PTH levels, measured by the IRMA technique, are
markedly lower in patients with adynamic lesions compared to
those with histologic evidence of secondary hyperparathyroid-
ism [5, 10].
In the current study, serum PTH levels above 200 pg/ml
strongly suggested the presence of high-turnover skeletal le-
sions of renal osteodystrophy in pediatric patients undergoing
CCPD. All patients with bone biopsy evidence of secondary
hyperparathyroidism had values exceeding 200 pg/mi, findings
consistent with those recently reported in children and adults
receiving regular hemodialysis [4, 9]. Although some patients
with normal bone histology also had serum PTH levels greater
than 200 pg/mi, none of those with adynamic lesions of bone
had values above this threshold. The specificity and positive
predictive value of serum PTH measurements for the non-
invasive diagnosis of hyperparathyroid bone disease was en-
hanced by including a second screening criterion; thus, the
combination of a serum PTH level above 200 pg/mi and a serum
calcium level less than 10 mg/dl correctly identified all patients
with bone biopsy evidence of secondary hyperparathyroidism,
and it excluded all patients with either normal or reduced rates
of bone formation.
The finding that bone formation remains normal despite
modest increases in serum PTH in some patients with end-stage
renal disease mdicates that PTH levels that are generally
associated with parathyroid bone disease in subjects with
normal renal function are not sufficient to induce this change in
children with chronic renal failure. This observation is consis-
tent with data recently reported by Quarles, Lobaugh and
Murphy, and it suggests that moderately elevated serum levels
of PTH are required to maintain bone formation and turnover
within the normal range in patients with chronic renal failure
[9].
For the assessment of low-turnover skeletal lesions, serum
PTH values below 200 pglml were 100% sensitive and 79%
specific, but the PPV was only 58% for patients with adynamic
lesions of renal osteodystrophy. Although all patients with bone
biopsy evidence of secondary hyperparathyroidism were ex-
cluded using this criterion alone, most patients with normal
bone histology also had serum PTH levels below 200 pg/mI.
Specificity for the diagnosis of the adynamic lesion increased to
89%, however, using the combined criteria of a serum PTH
level below 200 pg/mI and a serum calcium level above 10 mgldl.
Serum PTH values less than 150 pg/mi in combination with
serum calcium levels greater than 10 mg/dl were 80% sensitive
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but 92% specific for identifying patients with adynamic bone;
thus, PPV rose to 82% using these criteria.
In the current study, normal bone histology was present in
children with an average serum PTH level of 180 141 pg/mi,
whereas histologic evidence of secondary hyperparathyroidism
was not found until serum PTH levels exceeded 200 pg/mi. In
contrast, all patients with adynamic skeletal lesions had serum
PTH levels below 200 pg/mi and 11 of these had values below 65
pg/mi. Such findings not only provide an estimate of the skeletal
resistance to the actions of PTH in chronic renal failure but also
suggest a suitable therapeutic target range for PTH in children
with end-stage renal disease. Serum PTH levels approximately
three times the upper limit of normal appear to be functionally
appropriate with respect to the integrity of bone in pediatric
patients undergoing regular dialysis. Lowering PTH levels
further, however, by aggressive therapy with calcium carbonate
and 1,25(OH)2D may be associated with the development of
adynamic lesions. Whether this disorder adversely influences
longitudinal bone growth, the incidence of bone fractures or the
prevalence of skeletal deformity in children undergoing regular
dialysis, remains to be determined.
The results of the current investigation indicate that the
prevalence of the adynamic lesion of renal osteodystrophy has
increased only modestly during the last five years in children
undergoing regular peritoneal dialysis. Before 1987, when the
use of aluminum-containing, phosphate-binding antacids was
sharply curtailed, 7 of 63, or 11%, of pediatric patients at our
institution had histologic evidence of adynamic bone, and one
of these cases was due to excess bone aluminum deposition.
Since the beginning of 1987, when calcium carbonate was
adopted as the primary phosphate-binding agent, 14 of 93
patients undergoing bone biopsy, or 15%, had adynamic lesions
of renal osteodystrophy. Overall, the proportion of patients
with either normal bone histology or adynamic lesions was 27%
before 1987 and 35% thereafter.
These results are in striking contrast to data recently reported
by Sherrard et al, who found that 66% of adult patients
undergoing peritoneal dialysis had adynamic skeletal lesions
[5]. This discrepancy may be attributable, at least in part, to the
substantial number of adult patients with diabetes and/or evi-
dence of aluminum deposition in bone. In contrast, none of the
patients in the current study was diabetic, and aluminum-
containing, phosphate-binding antacids have been used infre-
quently during the past five to seven years at this facility in
children receiving regular dialysis. Moreover, some older adult
patients undergoing regular dialysis may have the syndrome of
osteoporosis with reduced rates of bone formation and turnover
unrelated to the presence of renal disease [22]. Adequate
distinction between adults with osteoporosis undergoing regular
dialysis and those with adynamic lesions of renal osteodystro-
phy may be quite difficult, even when assessments include bone
biopsy and histomorphometric analysis.
It has been suggested that adults receiving regular peritoneai
dialysis have a higher incidence of adynamic bone than those
managed by hemodialysis [5]. In the current study, the moder-
ate rise in the prevalence of adynamic lesions in children
evaluated after 1987 suggests that factors unrelated to perito-
neal dialysis per se account for this change since all biopsy data
for the current report were obtained from patients undergoing
CAPD or CCPD. The increased use of large doses of oral
calcium carbonate and/or more aggressive treatment with active
vitamin D sterols, particularly calcitriol, are more likely con-
tributors to the changing pattern of renal osteodystrophy in
patients managed by peritoneal dialysis [5, 8, 10].
The system of classification of renal osteodystrophy used in
the current and previous studies from this laboratory includes a
subgroup with normal bone histology [2]; such patients have no
overt histologic evidence of renal osteodystrophy, and tetracy-
cline-based measurements of the rate of bone formation fall
within the range seen in normal subjects without renal failure.
Other investigators have generally not described a similar
subgroup of patients [3, 5, 10]. The distinction between the
adynamic lesion of renal osteodystrophy and normal bone
histology requires adequate normative data for both histologic
indices and tetracycline-based measurements of bone forma-
tion. Differences between the current results in children and
those described in adults may, in part, be due to variations in
the criteria used for histologic classification [3, 5, 10].
In the past, the finding of relatively low serum PTH levels in
patients with chronic renal failure suggested the presence of
aluminum toxicity and aluminum-related bone disease [23].
With recognition that the long-term use of oral aluminum-
containing, phosphate-binding antacids can lead to the devel-
opment of aluminum intoxication [24, 25], alternative phos-
phate-binding agents which do not contain aluminum have been
widely utilized [26—28]. The results of the current investigation
indicate that relatively low serum PTH levels are a feature of
adynamic bone, even in the absence of aluminum intoxication.
Such patients commonly develop hypercalcemia which cannot
be ascribed to excess PTH secretion; accordingly, parathyroid-
ectomy is not indicated in such patients. The diagnostic criteria
described in the current report should be of value for the
non-invasive assessment of children with adynamic skeletal
lesions of renal osteodystrophy; these criteria may also serve to
distinguish between patients with adynamic lesions of bone and
those with overt secondary hyperparathyroidism.
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